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ABSTRACT
Between October 2001 and August 2002, 30 hospital patients became infected or colonised by a
multiresistant (including to carbapenems) epidemic strain of Acinetobacter baumannii (AbMR) in a
hospital outbreak. This study analysed the risk-factors associated with acquisition of this epidemic strain
and investigated the prognosis of patients infected by AbMR, with the aim of elucidating factors which
lead to mortality. A case-control study of the acquisition of AbMR in patients infected or colonised in the
hospital outbreak was performed. Independent risk-factors leading to death were studied by logistic
regression analysis. Multivariate analysis of the risk-factors for colonisation ⁄ infection with AbMR
revealed an independent association with the presence of an arterial catheter (OR, 1.13; 95% CI, 1.03–
1.25) and administration of imipenem as monotherapy (OR, 11.12; 95% CI, 2.33–53.09). Multivariate
analysis of the prognostic features leading to mortality revealed a significant association with
hypotension or shock (OR, 24.63; 95% CI, 1.56–387.56) at the time of bacterial isolation.
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INTRODUCTION
In recent years there has been an increase in the
number of nosocomial infections caused by Aci-
netobacter baumannii, particularly bacteraemia
[1–4] and pneumonia [5,6] in patients admitted
to intensive care units (ICUs) and resuscitation
units (RUs) [2]. A. baumannii is important because,
although not considered to be particularly viru-
lent, it is a nosocomial pathogen that is difficult to
control [5,7]. In certain ICUs, A. baumannii, asso-
ciated previously with sporadic outbreaks of
infection, is now the cause of endemic, polyclonal
outbreaks [5]. Treatment of such infections caused
by A. baumannii can be particularly difficult
because of the frequently multidrug-resistant
nature of these organisms. Carbapenems are
usually the antibiotics of choice for treating
serious infections caused by A. baumannii, but
resistance to these compounds in A. baumannii is
now increasing worldwide. Consequently, sul-
bactam [8–12] and colistin [13,14] are sometimes
used to treat A. baumannii infections when no
alternative agents are available.
Although there have been several epidemio-
logical–clinical studies of endemic A. baumannii
strains of polyclonal origin [2,5,15–17], fewer
studies have examined outbreaks caused by a
single strain [7,15]. By their very nature, studies
of the latter type do not involve variations in the
virulence of strains contained in polyclonal
populations. Such studies allow analysis of any
association between risk-factors for colonisa-
tion ⁄ infection, prognostic factors, and various
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external factors, including the host, without
considering the microorganism itself.
Between October 2001 and August 2002, 30
patients from Juan Canalejo Hospital complex (La
Corun˜a, north-west Spain) became infected and ⁄
or colonised with an epidemic multiresistant
A. baumannii strain (AbMR). The aims of the
present study were: (1) to characterise the epide-
miological features of the outbreak; (2) to deter-
mine the risk-factors for infection and ⁄ or
colonisation by the strain causing the outbreak;
and (3) to analyse the clinical features of the
patients infected by the AbMR strain causing the
outbreak, so that the prognostic factors associated
with mortality could be determined.
MATERIALS AND METHODS
Study setting and selection criteria
Between October 2001 and August 2002, 30 patients admitted
to the RU and ICU at the Juan Canalejo Hospital complex (a
tertiary-level, 1200-bed hospital serving a population of
516 000 inhabitants) were infected and ⁄or colonised by an
epidemic AbMR strain. These 30 patients were designated as
cases, while 31 patients admitted to the same units during the
same period, from whom non-Acinetobacter microbial species
or A. baumannii isolates sensitive to carbapenems were
obtained, were chosen at random as controls. The control
patients matched the cases, except that the epidemic AbMR
strain was isolated from the cases.
Measurements
Infection or colonisation with AbMR was documented by the
Infectious Diseases Unit. A series of concepts was established for
the study. First, the base mortality rate at 30 days after diagnosis
was determined; this was considered independently of whether
mortality was related to the presence ofA. baumannii, because of
the difficulty in establishing whether infection was the cause of
death in seriously ill patients with poor prognoses. Second,
attributable mortality was defined as the difference in mortality
between the cases and controls. Third, related mortality was
recorded when infection ⁄ colonisation was established, by clin-
ical criteria, as the primary cause of death. As a variable of
prognostic interest, the post-diagnostic hospital stay of the
survivors was compared with that of the control patients to
obtain the attributable hospital stay, which was used to
determine whether infection ⁄ colonisation by A. baumannii led
to a worse prognosis than infection by other bacteria in critically-
ill patients.
The variables studied to determine the risk-factors for
infection ⁄ colonisation by AbMR and for the descriptive study
of the clinical characteristics of the infected and ⁄ or colonised
patients, as well as the associated prognostic factors, were as
follows (all prior to diagnosis of infection ⁄ colonisation by
AbMR): age, gender, number of days in ICU ⁄RU, recent
(< 7 days) surgery, presence and duration of invasive proce-
dures (bladder probe, parenteral nutrition, intubation or
tracheotomy, and arterial catheter), duration and administra-
tion of antibiotics (amoxycillin–clavulanic acid, piperacillin–
tazobactam, cefepime, imipenem, ciprofloxacin, vancomycin
and amikacin), McCabe and Jackson’s classification (non-fatal
disease, ultimately fatal disease, and rapidly fatal underlying
disease), diabetes or hyperglycaemia of > 250 mg ⁄dL, chronic
pulmonary disease, cardiopulmonary diseases, solid tumours,
haematological diseases, immunological status, and admis-
sion to ICU or RU. Other variables included in the study
were: the type of sample from which the AbMR strain was
isolated, type of presentation (infection or colonisation),
hypotension or septic shock around the time of diagnosis of
infection ⁄ colonisation, presence and duration of invasive
procedures before the diagnosis, antibiotic administration
before the diagnosis, isolation of patients, microbiological
cultures used for monitoring of patients, and eradication of
the AbMR strain.
The measures taken to control the outbreak were in
accordance with those recommended previously [5]. Infec-
ted ⁄ colonised patients were isolated and measures were taken
to prevent contact with the AbMR strain (use of disposable
gloves to examine infected ⁄ colonised patients, cleaning and
disinfection of surfaces, etc.).
Microbiological analysis
All isolates of the outbreak strain (AbMR) were obtained
from clinical specimens. Microbiological samples were
obtained weekly from the most common sites of colonisa-
tion, i.e., pharyngeal, axillary and perineal smears. Rectal
and gastric samples were not taken. Isolates were identified
phenotypically by the DadeMicroScan system (Baxter Health
Care, West Sacramento, CA, USA) and the API 20NE system
(bioMe´rieux, Marcy l’Etoile, France), with subsequent con-
firmation as A. baumannii by amplified ribosomal DNA
restriction analysis [18]. Antibiotic susceptibilities were
determined by microdilution using the DadeMicroScan Neg
Breakpoint Combo Panel 2I, with MICs confirmed by Etests
(AB Biodisk, Dalva¨gen, Sweden). The criteria proposed by
the NCCLS [19] were applied in interpreting the sensitivity
results. Molecular typing of the isolates (one per patient)
was performed by REP-PCR [20–22], with REP-PCR DNA
band patterns being resolved by electrophoresis on agarose
0.8% w ⁄v gels.
Antibiotic use
The parameter for antibiotic use was established as the daily
defined dose (DDD) ⁄ service during a period of 1 month; this
was calculated in terms of the total amount (in grams) of an
antibiotic agent administered, using the definition provided by
the WHO [23].
Statistical analysis
Univariate analysis was performed to determine the variables
associated significantly with colonisation ⁄ infection by AbMR,
as well as the resulting prognostic factors. Contingency tables
were analysed by a two-tailed chi-square test or by Fisher’s
exact test. Quantitative variable differences between case and
control patients were compared by Student’s t-test or the
Mann–Whitney test, as appropriate. The Kolmogorov–Smir-
nov test was used to assess normality.
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A multiple-regression logistic model was developed to
identify the potential independent factors associated with
colonisation ⁄ infection by AbMR, as well as the prognostic
factors. A forward stepwise strategy was followed, adjusting
for all variables that were statistically significant in the
univariate analysis or that were clinically relevant, with 95%
CIs calculated as estimators. Two-sided tests were used for all
analyses. Results were considered statistically significant at
p < 0.05. Data were stored and analysed using SPSS software
v. 11.5 (Analytical Software, St Paul, MN, USA).
RESULTS
Descriptive clinical study and prognosis
During the study period, 30 patients became
infected or colonised by the epidemic strain of
AbMR (Table 1). Infection and ⁄ or colonisation
was observed more frequently in men (80%), with
the average age being 57.1 ± 15.7 years. Of the
patients affected by AbMR, 52% had underlying
illnesses, most commonly chronic, non-fatal car-
diopulmonary disease, while 26.7% were immu-
nosuppressed. The most common cause of
admission for the study patients was multiple
fractures, with most patients having been admit-
ted to the ICU. Invasive procedures were used in
90% of the patients, and 80% received antibiotic
polytherapy. In total, 53.3% of the patients were
colonised (i.e., did not show clinical symptoms of
infection at the time of isolation) and 46.7% were
infected by the AbMR strain responsible for the
outbreak. AbMR was isolated most frequently
from respiratory exudates (Table 1). Respiratory
isolates were recovered from 53% of the patients.
Of the infected and ⁄ or colonised patients, 43.3%
died.
Antimicrobial susceptibilities, molecular
epidemiology and characterisation of the
outbreak
The A. baumannii isolates showed high levels of
resistance to all b-lactams (with the exception of
ampicillin–sulbactam), quinolones and aminogly-
cosides (but intermediate resistance to tobramy-
cin); the isolates were sensitive only to colistin.
MICs (mg ⁄L) were as follows: amoxycillin > 256;
piperacillin > 256; ceftazidime 128; cefepime 64;
aztreonam 256; imipenem 32; meropenem
64; ampicillin–sulbactam 12 ⁄ 6; tobramycin 8;
amikacin 64; ciprofloxacin > 32; and colistin 2.
The first isolate from each patient was typed by
REP-PCR. The date of isolation of each AbMR
isolate, the clinic where the isolation was made
and the type of sample from which the isolate was
recovered are shown in Table 1. All 30 AbMR
isolates belonged to a single genotype. Three
different samples of each isolate were tested, with
identical results on each occasion (data not
shown).
Most of the isolates were from patients in two
areas of the hospital, namely the ICU and the RU,
although the strain may have been disseminated
within the hospital, as six patients in different
parts of the hospital were also found to be carriers
of the strain; these patients had previously been
admitted to the RU (n = 2) or the ICU (n = 4).
Risk-factors associated with infection or
colonisation by the epidemic AbMR strain
In the study of case-controls, the qualitative vari-
ables that showed statistical significance (p < 0.05)
were the presence of an intravascular catheter,
intubation or tracheostomy, and administration of
antibiotics, specifically amikacin, vancomycin and
imipenem (Table 2). The significant quantitative
variables were the number of days of hospitalisa-
Table 1. Acinetobacter baumannii isolates included in the
REP-PCR analysis
Isolate
Date of isolation
(day ⁄month ⁄ year) Hospital ward Sample
1 17 ⁄ 10 ⁄ 2001 ICU Catheter
2 27 ⁄ 11 ⁄ 2001 RU Tracheal exudate
3 5 ⁄ 12 ⁄ 2001 RU Bronchial aspirate
4 17 ⁄ 12 ⁄ 2001 RU Bronchial secretion
5 17 ⁄ 12 ⁄ 2001 ICU Catheter
6 27 ⁄ 12 ⁄ 2001 ICU Bronchial aspirate
7 28 ⁄ 12 ⁄ 2001 General surgerya Peritoneal fluid
8 3 ⁄ 1 ⁄ 2002 ICU Bronchial aspirate
9 8 ⁄ 1 ⁄ 2002 ICU Bronchial secretion
10 11 ⁄ 1 ⁄ 2002 ICU Cerebrospinal fluid
11 21 ⁄ 1 ⁄ 2002 ICU Bronchial secretion
12 22 ⁄ 1 ⁄ 2002 ICU Catheter
13 24 ⁄ 1 ⁄ 2002 Orthopaedic surgeryb Wound exudate
14 24 ⁄ 1 ⁄ 2002 Neurologyb Axillary smear
15 20 ⁄ 2 ⁄ 2002 ICU Bronchial secretion
16 8 ⁄ 2 ⁄ 2002 RU Ulcers
17 13 ⁄ 2 ⁄ 2002 ICU Bronchial aspirate
18 14 ⁄ 2 ⁄ 2002 RU Catheter
19 15 ⁄ 2 ⁄ 2002 ICU Catheter
20 26 ⁄ 3 ⁄ 2002 ICU Bronchial secretion
21 19 ⁄ 4 ⁄ 2002 RU Catheter
22 24 ⁄ 4 ⁄ 2002 ICU Axillary smear
23 24 ⁄ 4 ⁄ 2002 ICU-Hosp2b Perineal exudate
24 6 ⁄ 5 ⁄ 2002 ICU Urine
25 8 ⁄ 5 ⁄ 2002 RU Peritoneal fluid
26 17 ⁄ 5 ⁄ 2002 Oncologyb Wound exudate
27 20 ⁄ 5 ⁄ 2002 RU Bronchial aspirate
28 20 ⁄ 5 ⁄ 2002 RU Catheter
29 30 ⁄ 8 ⁄ 2002 Gastroenterologya Wound exudate
30 30 ⁄ 8 ⁄ 2002 RU Bronchial aspirate
ICU, intensive care unit; RU, resuscitation unit.
aPrevious admission to RU.
bOther hospital in a physically separated area. Previous admission to ICU.
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tion or with a vesical catheter, parenteral nutrition
and intubation or tracheostomy (Table 3).
The variables found to be relevant were fitted
to a logistic regression model, which revealed that
the predictive variables for infection and ⁄ or col-
onisation by AbMR were the presence of an
arterial catheter prior to isolation (OR, 1.13; 95%
CI, 1.03–1.24) and the administration of imipenem
prior to isolation (OR, 11.12; 95% CI, 2.33–53.09)
(Table 4).
During September 2001, i.e., 1 month before the
start of the outbreak, there was an increase in the
use of carbapenems in the hospital, compared
with the consumption in previous months. In the
RU, consumption in September was a DDD of
108, compared with a DDD of 127 in the ICU. The
average consumption in the 8 months preceding
September was a DDD of 94 for the RU, and of 46
for the ICU.
Prognostic factors
The univariate analysis showed that administra-
tion of vancomycin was associated with a high
level of mortality (OR, 5.40; 95% CI, 1.12–26.04).
The occurrence of hypotension or shock in the
48 h around the time of isolation was also
associated with patient mortality (OR, 8.75; 95%
CI, 1.36–54.79) (Table 5).
The logistic regression model revealed that the
significant associated prognostic factors were
hypotension or septic shock around the time of
isolation of the bacterial strain (Table 6). It is
important to emphasise that, although the use of
imipenem was of borderline significance, use of
this antibiotic in polytherapy showed a beneficial
effect (see Discussion).
The prognosis for patients infected ⁄ colonised
by AbMR was worse than that for the control
patients; infection ⁄ colonisation by AbMR was
associated with an excess mortality rate of
24.3% and an additional hospital stay of 14 days
compared with the control group of patients.
Other prognostic factors established were a base
mortality rate of 43.3% and a post-diagnostic
hospital stay of 28 days.
Table 2. Qualitative comparisons between case and con-
trol patients before isolation of the epidemic multiresistant
Acinetobacter baumannii strain
Variables
Cases
(n = 30)
n (%)
Controls
(n = 31)
n (%) p OR 95% CI
Gender
Male 24 (80) 23 (74.2) 0.590 0.71 0.21–2.40
Female 6 (20) 8 (25.8)
McCabe’s classification
Non-fatal 13 (43.3) 25 (80.6) NC NC NC
Ultimately fatal 3 (10) 1 (3.2) NC NC NC
Underlying rapidly
fatal disease
0 0 NC NC NC
Diabetes 6 (20) 3 (9.7) 0.301 2.33 0.52–10.34
Chronic pulmonary disease 1 (3.3) 5 (16.1) 0.195 0.17 0.02–1.63
Cardiovascular disease 10 (33.3) 8 (25.8) 0.519 1.43 0.47–4.34
Solid tumour 2 (6.6) 5 (16.1) 0.707 0.57 0.12–2.66
Haematological malignancy 1 (3.3) 0 0.492
Immunosuppression 8 (26.7) 8 (25.8) 0.939 1.04 0.33–3.27
Urinary catheter 28 (93.3) 28 (90.3) 1.000 1.50 0.23–9.67
Intravascular catheter 26 (86.7) 13 (41.9) < 0.001 9.00 2.52–32.10
Parenteral nutrition 30 (100) 29 (93.5) 0.492 NC NC
Intubation ⁄ tracheostomy 30 (100) 23 (74.2) 0.005 NC NC
Use of carbapenems 19 (63.3) 3 (9.7) < 0.001 16.12 3.96–65.58
Use of
piperacillin–tazobactam
1 (3.3) 3 (9.7) 0.612 0.32 0.03–3.28
Use of cefepime 3 (10) 2 (6.5) 0.671 1.61 0.25–10.39
Use of
amoxycillin–clavulanate
10 (33.3) 10 (32.2) 0.929 1.05 0.36–3.05
Use of ciprofloxacin 8 (26.7) 3 (9.7) 0.084 3.39 0.08–14.32
Use of vancomycin 11 (36.7) 3 (9.7) 0.012 5.40 1.33–21.98
Use of amikacin 10 (33.3) 2 (6.5) 0.008 7.25 1.43–36.69
Use of imipenem 18 (60) 3 (9.7) < 0.001 14.00 3.46–56.59
NC, not calculable.
Table 3. Quantitative comparisons
between case and control patients
before isolation of the epidemic
multiresistant Acinetobacter bauman-
nii strain
Variables
Cases (n = 30) Controls (n = 31)
pMean (SD) Median Mean (SD) Median
Age 57.06 (15.70) 60.50 57.83 (12.85) 58.00 0.902
Days in ICU 21.36 (10.92) 21.00 11.64 (11.92) 9.00 0.001
Days with urinary catheter 16.96 (11.43) 14.50 9.07 (9.10) 7.50 0.009
Days with arterial catheter 15.73 (9.17) 14.00 9.92 (7.93) 9.00 0.058
Days with parenteral nutrition 19.33 (10.47) 18.00 16.72 (33.63) 6.00 0.003
Days with intubation ⁄ tracheostomy 19.13 (9.76) 19.50 11.86 (12.86) 6.00 0.004
Days of use of amikacin 10.70 (10.58) 5.50 7.50 (7.77) 7.50 0.513
Days of use of ciproflaxacin 9.62 (5.73) 8.50 5.25 (3.94) 4.00 0.173
Days of use of imipenem 12.76 (7.87) 11.00 7.33 (6.11) 6.00 0.223
ICU, intensive care unit.
Table 4. Association among risk-factors for infection ⁄ col-
onisation by the epidemic multiresistant Acinetobacter
baumannii strain (multivariate analysis)
p OR 95% CI (OR)
No. of days in ICU 0.278 1.05 0.96–1.14
Presence of urinary catheter 0.776 0.98 0.90–1.07
Presence of arterial catheter 0.011 1.13 1.03–1.24
Presence of intubation ⁄ tracheostomy 0.784 1.01 0.92–1.11
Administration of imipenem 0.003 11.12 2.33–53.09
ICU, intensive care unit.
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DISCUSSION
Recent studies have shown that A. baumannii has
progressed from causing sporadic nosocomial
outbreaks, associated with environmental reser-
voirs, to causing worldwide nosocomial out-
breaks [5,7,15,24]. In the present study, all of the
patients were infected ⁄ colonised by the same
AbMR strain. This strain was isolated from some
patients who were undergoing treatment in hos-
pital wards other than the ICU and RU, e.g.,
neurology, orthopaedics and oncology, but the
outbreak strain did not spread in any of these
departments. All of the infected ⁄ colonised
patients in these wards had been admitted previ-
ously to the ICU or RU. The consumption of
carbapenems in the ICU and the RU had
increased in the month preceding the outbreak,
but it is not clear whether this was related to the
onset of the outbreak. Previous studies have
established that infected ⁄ colonised patients
themselves are the main reservoir of AbMR, with
the main route of transmission being the hands of
hospital personnel [15]. Surrounding inanimate
objects act as an intermediate reservoir between
the hands of hospital workers and the patients
[25].
Logistic regression analysis revealed that the
most important risk-factors for infection and ⁄ or
colonisation by the AbMR strain were the pres-
ence of an arterial catheter and, particularly, the
administration of imipenem before isolation of
the organism (an 11-fold increased risk of being
infected and ⁄ or colonised by the outbreak AbMR
strain compared with patients who did not
receive this antibiotic). Approximately 80% of
the infected and ⁄ or colonised patients were
suffering from a variety of underlying illnesses,
particularly cardiopulmonary disease. All of
these findings are consistent with those of
previous studies [2,5,16,26]. It is characteristic
that the principal form of clinical presentation of
AbMR in the outbreak was colonisation (53.3%)
rather than infection (46.7%), demonstrating the
high capacity of this organism to colonise
patients.
When the variables were fitted to the logistic
regression model, it was found that only one
variable was associated significantly with mortal-
ity caused by the outbreak strain of AbMR,
namely the occurrence of hypotension or shock.
Although the administration of imipenem was
not a statistically significant prognostic factor, it
was a protective factor from a clinical perspective
(OR, 0.09). However, this appears to be contra-
dictory, as the administration of carbapenems
also appears to be a major risk-factor for infection
and ⁄ or colonisation by AbMR. Administration of
imipenem before isolation of the AbMR strain
was principally in the form of monotherapy. In
contrast, following isolation of the outbreak
strain, combination therapy was administered. A
second important finding was the observation
that hypotension or shock resulted in a 24-fold
increase in the probability of mortality.
In the present study, the base mortality rate was
43.3%, the related mortality rate was 30%, and the
attributable mortality rate was 24.3%. These
results show the important degree of morbidity
and mortality caused by A. baumannii infection in
patients admitted to ICUs. Using the concepts of
post-diagnostic hospital stay (28 days) and attrib-
utable hospital stay (14 days), it was established
Table 5. Comparison of prognostic factors for patients
who died (mean age 63.23 years; median 67 years) and
patients who survived (mean age 52.35 years; median
53 years; p 0.086)
Patients
who
died
(n = 13)
Patients
who
survived
(n = 17)
p OR (95% CI)n % n %
McCabe’s classification
Non-fatal 6 46.15 7 41.17 NC NC
Ultimately fatal 3 23.07 0 – NC NC
Rapidly fatal
underlying disease
0 0 0 0 NC NC
Use of ampicillin–sulbactam 5 38.46 4 23.52 0.433 2.03 (0.41–9.88)
Use of colistin 2 15.38 2 11.76 1.000 1.36 (0.17–11.23)
Use of imipenem 5 38.46 11 64.70 0.153 0.34 (0.07–1.52)
Use of vancomycin 9 69.23 5 29.41 0.03 5.40 (1.12–26.04)
Hypotension or
shock around the time
of isolation of the
epidemic AbMR strain
7 53.84 2 11.76 0.013 8.75 (1.36–54.79)
Presentation
Infection 5 38.46 9 52.94 0.431 0.55 (0.12–2.41)
Colonisation 8 61.53 8 47.06 0.431 0.55 (0.12–2.41)
AbMR, multiresistant Acinetobacter baumannii.
NC, not calculable.
Table 6. Association among prognostic factors for pre-
dicting the probability of death (multivariate analysis)
p OR 95% CI (OR)
Use of imipenem 0.058 0.09 0.007–1.08
Use of vancomycin 0.101 5.11 0.72–35.89
Hypotension or shocka 0.023 24.63 1.56–387.56
aWithin 48 h of isolation of the epidemic multiresistant Acinetobacter baumannii
strain.
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that the prognosis for critically-ill patients infected
and ⁄ or colonised by A. baumannii was worse than
that for similar patients infected by other bacteria.
Interestingly, the AbMR strain isolated from
patients who died following septic shock (83%)
was obtained from normally sterile clinical sam-
ples (peritoneal liquid and cerebrospinal fluid) in
50% of the cases, whereas isolation was from non-
sterile sites of the other patients. Together, these
results indicate that the outbreak of A. baumannii
in the present study was associated with mortality
in the infected patients, and that whether or not
patients survived or died may have depended on
the site of infection rather than antibiotic treat-
ment, particularly as no differences in antibiotic
treatment were observed between the patient
groups (data not shown).
In summary, the conclusions of this study were:
(1) that the main risk-factor associated with the
acquisition of the AbMR strain was the adminis-
tration of imipenem as monotherapy; (2) that the
AbMR strain responsible for the outbreak caused
septic shock in 16.6% of cases, with a high
associated rate of morbidity ⁄mortality; (3) that a
high mortality rate and a relatively long hospital
stay were attributable to infection and ⁄ or coloni-
sation by AbMR; (4) that administration of
antimicrobial polytherapy, i.e., imipenem in com-
bination with sulbactam, colistin or aminoglyco-
sides, eradicated the multiresistant strain
successfully in 30% of cases; and (5) that hypo-
tension or septic shock around the time of
isolation of the bacterial strain was a significant
prognostic factor.
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